REFERENCES
1. S.T. Crooke et al., "Mechanisms of Antisense Drug Action, an Introduction," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 3–47.
2. S.M. Elbashir et al., Nature 411 (6386), 494–498 (2001).
3. A. Jackson and P.S. Linsley, Discovery Medicine 9 (47), 311–318 (2010).
4. J. Krutzfeldt et al., Nature 438 (7068), 685–689 (2005).
5. D.P. Bartel, Cell 116 (2), 281–297 (2004).
6. E.C. Lai, Nat. Rev. Genet 30 (4), 363–364 (2002).
7. T. Thum et al., Nature 456 (7224), 980–984 (2008).
8. L. Ma et al., Nature 28 (4), 341–347 (2010).
9. R.E. Lanford et al., Science 327 (5962), 198–201 (2010).
10. P.P. Seth et al., J. Med. Chem. 52 (1), 10–13 (2009).
11. A.A. Levin, R. Zu, and R.S. Geary, "Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs," in
Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 183–215.
12. B. Monia et al. J. Biol. Chem. 268 (19), 14514–14522 (1993).
13. R.S. Geary, R. Zu, and A.A. Levin, "Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2'-O-(2-Methoxyethyl)-Modified
Antisense Oligonucleotides in Animals and Man," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 306–326.
14. S.C. Semple et al., Nature Biotech. 28 (2), 172–176 (2010).
15. S.V. Dongen et al., Nature Methods 5 (12) 1023–1025 (2008).
|
